ARCHIVES

FDA Plans Greater Disclosures Over Wide Range Of Activities

This article is from The Cancer Letter archive.

Vol. 36 No. 19 | May 21, 2010

Download PDF Visit The Full Archive

Related Articles

Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate

March 25, 2011

NCI director apologizes to cancer centers for inaction on working group report.

October 31, 2003

U. S. Oncologists To Audit Another Bezwoda Trial.

November 10, 2000

Sirolimus-Containing Therapy Reduces GVHD, Study Finds

January 31, 2003

CIS Celebrates 15th Anniversary, Praised By M. Quayle

December 6, 1991

Part II of Q&A With NCI Director Harold Varmus

July 29, 2011